Register for free
Recent Quotes
My Watchlist
Indicators
Business Insurance Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Qiagen N.V. Common Shares (NY:QGEN)

44.67 -0.77 (-1.69%)
Streaming Delayed Price Updated: 2:44 PM EST, Dec 16, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Qiagen N.V. Common Shares

< Previous 1 2 3 4 5 6 7 8 Next >
News headline image
QIAGEN Launches Syndromic Test For QIAstat-Dx For Six Pathogens Similar To Monkeypox ↗
 
Via Benzinga
News headline image
QIAGEN Launches Syndromic Test for QIAstat-Dx Device to Combat Global Monkeypox Health Emergency
From QIAGEN N.V.
Via Business Wire
News headline image
Qiagen Posts Robust Q2 Non-COVID Sales Growth, Lifts Annual Guidance ↗
Qiagen N.V. (NYSE: QGEN) clocked Q2 FY22 revenues of $516 million, down 9% Y/Y, well above the consensus of $488.73 million. 
Via Benzinga
News headline image
QIAGEN adds new biopharma products to QIAcuity digital PCR portfolio and launches Expert Custom Assay Design Service
From QIAGEN N.V.
Via Business Wire
News headline image
QIAGEN beats outlook for Q2 2022 and raises full-year 2022 outlook
From QIAGEN N.V.
Via Business Wire
News headline image
Natera Clocks 28% Jump In Q1 Sales, Lifts FY22 Guidance ↗
 
Via Benzinga
News headline image
Qiagen Posts Upbeat Q1 Earnings, Raises FY22 Outlook ↗
 
Via Benzinga
News headline image
QIAGEN’s Clinical Decision Support Platform QCI Surpasses Three Million NGS Patient Test Cases
From QIAGEN N.V.
Via Business Wire
News headline image
QIAGEN N.V. to Release Results for Q2 2022 and Hold Webcast
From QIAGEN N.V.
Via Business Wire
News headline image
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday ↗
Good morning, investor! We're back with a breakdown of the biggest pre-market stock movers for Tuesday to get the day started! 
Via InvestorPlace
News headline image
U.S. CDC Endorses the Use of Digital PCR Technology for Wastewater Surveillance of Infectious Diseases – Including COVID-19 Outbreaks
From QIAGEN N.V.
Via Business Wire
News headline image
QIAGEN’s Eco-Friendlier Products Earn Prestigious ACT Label
From QIAGEN N.V.
Via Business Wire
News headline image
QIAGEN Expands Syndromic Testing Portfolio with the Launch of Higher-Capacity QIAstat-Dx Rise and Enhanced Panels
From QIAGEN N.V.
Via Business Wire
News headline image
QIAGEN Acquires Majority Stake in Enzymes Provider BLIRT S.A.
From QIAGEN N.V.
Via Business Wire
News headline image
QIAGEN Proposes Expansion of Supervisory Board
From QIAGEN N.V.
Via Business Wire
News headline image
QIAGEN Adds HSV1/2 Herpes Assay With CE-IVD Certification for Use on NeuMoDx Integrated PCR System
From QIAGEN N.V.
Via Business Wire
News headline image
QIAGEN exceeds outlook for Q1 2022, delivers strong 14% CER sales growth from non-COVID products and increases full-year outlook
From QIAGEN N.V.
Via Business Wire
News headline image
QIAGEN N.V. to release results for Q1 2022 and hold Webcast
From QIAGEN N.V.
Via Business Wire
News headline image
QIAGEN Reaches Milestone With 100 Million QuantiFERON Tests Used to Detect TB
From QIAGEN N.V.
Via Business Wire
News headline image
Earnings Scheduled For April 27, 2022 ↗
Companies Reporting Before The Bell • Deutsche Bank (NYSE:DB) is projected to report earnings for its first quarter. 
Via Benzinga
News headline image
QIAGEN Announces 20-F Annual Report Filing for 2021 Results
From QIAGEN N.V.
Via Business Wire
News headline image
Death Cross Looms Over Qiagen Investors ↗
If history is any guide, there may be trouble ahead for shares of Qiagen (NYSE:QGEN). A so-called "death cross" has formed on its chart and, not surprisingly, this could be... 
Via Benzinga
News headline image
The Daily Biotech Pulse: Bristol-Myers Squibb Announces $5B Accelerated Buyback, Qiagen Reaps COVID Testing Windfall, WORLDSymposium Presentations Kick In ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
News headline image
Qiagen Q4 Earnings Beat Expectations On High Demand For COVID-19 Tests, Issues FY22 Guidance ↗
Qiagen N.V. (NYSE: QGEN)  
Via Benzinga
News headline image
Qiagen: Q4 Earnings Insights ↗
Qiagen (NYSE:QGEN) reported its Q4 earnings results on Tuesday, February 8, 2022 at 04:05 PM. Here's what investors need to know about the announcement. Earnings Qiagen beat estimated earnings by... 
Via Benzinga
News headline image
QIAGEN beats outlook for fourth quarter and full-year 2021, delivers 22% CER full-year sales growth from non-COVID products
From QIAGEN N.V.
Via Business Wire
News headline image
The Daily Biotech Pulse: Pfizer, Amgen Shares Slip On Earnings, Editas Terminates Chief Medical Officer, Biogen Licenses Preclinical Rheumatoid Arthritis Biosimilar ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
News headline image
Qiagen's Earnings: A Preview ↗
Qiagen (NYSE:QGEN) is set to give its latest quarterly earnings report on Tuesday, 2022-02-08. Here's what investors need to know before the announcement. Analysts estimate that Qiagen will likely... 
Via Benzinga
News headline image
Earnings Scheduled For February 8, 2022 ↗
Companies Reporting Before The Bell • Pfizer (NYSE:PFE) is likely to report quarterly earnings at $0.87 per share on revenue of $24.20 billion. 
Via Benzinga
News headline image
QIAGEN’s New Generation of QuantiFERON TB Test Gains Chinese Approval and Renewed WHO Recommendation
From QIAGEN N.V.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.

Never miss important news. Subscribe to our newsletter.
Register for free

Information

Copyright 2024. BUSINESS INSURANCE HOLDINGS